✨
AI Summary
- Rare pediatric disease PRV deadline approaches; potential Makena compounding ban.
- Discusses the potential sunsetting of the FDA's rare pediatric disease voucher program.
- Considers the implications of banning compounding for the withdrawn Makena drug.